1381P - Perceptions of clinical trials in Asian cancer patients: a comprehensive survey in a Korean tertiary hospital

Date 30 September 2012
Event ESMO Congress 2012
Session Poster presentation II
Topics Patient Education and Advocacy
Presenter Su Jin Lee
Authors S.J. Lee1, L.C. Park2, J. Lee1, S. Kim3, S. Kim1, W. Chang1, Y.S. Park1
  • 1Medicine, Samsung Medical Center, 135-710 - Seoul/KR
  • 2Internal Medicine, Kosin University Gospel Hospital, Busan/KR
  • 3Biostatistics Team, Samsung Medical Center, Seoul/KR



In the past few years, the number of clinical trials has increased rapidly in East Asia, especially for cancer types such as gastric and hepatobiliary cancer that are prevalent in Asian populations. However, the actual degree of understanding or perceptions of clinical trials by cancer patients in East Asian countries have seldom been studied.


Between July 1st 2011 and November 30th 2011, we conducted a prospective study to survey cancer patients regarding their awareness of, and willingness to participate in, a clinical trial. The questionnaire consisted of 21 questions based on an Index of Clinical Trial Understanding. Patients with gastrointestinal/hepatobiliary cancer who visited the Hematology-Oncology outpatient clinic at Samsung Medical Center (SMC) and who signed an informed consent form were enrolled. The survey was conducted by a well-trained research nurse and the data were statistically analyzed at the biostatistics core at SMC.


In this survey study, 1,000 patients were asked to participate and 675 patients consented to participate (67.5%). The awareness of clinical trials was substantially higher in patients who had a higher level of education (p < 0.001), were married (p = 0.004), and had a higher economic status (p = 0.001). Willingness to participate in a clinical trial was not significantly increased by higher level of education (p = 0.286), marital status (p = 0.685), or economic status (p = 0.310). The most common source for acquisition of clinical trial knowledge was attending physicians (52.0%) followed by mass media (36.6%), other patients (6.39%), the internet (3.3%), and other sources (1.5%). The most influential factors for patient's willingness to participate were physician's opinion (N = 181, 26.8%), limited treatment options (N = 178, 26.4%), and expectations of effectiveness of new anti-cancer drugs (N = 142, 21.0%). Patients were likely to refuse to participate in a clinical trial due to unverified treatment modality (N = 320, 47.4%) and negativity toward clinical trials (N = 193, 28.6%).


We surveyed a large patient cohort to specifically inquire about willingness to participate in, and awareness of, clinical trials in patients with Asian-prevalent cancer types. Further correlative analyses with diverse variables will be presented at the meeting.


All authors have declared no conflicts of interest.